# Prime Medicine, Inc.: overview

PRME · Nasdaq · CIK 1894562 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prme.md) · [Financials](/companies/prme/financials.md) · [Filings](/companies/prme/filings.md) · [Insiders](/companies/prme/insiders.md)

Latest reported revenue: [$838.0k](/filings/0001628280-26-013569.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-013569).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001628280-25-050422.md) | [2.2 d](/filings/0001628280-26-013569.md) | [1.5](/filings/0001628280-25-023486.md) | [1.1](/filings/0001628280-25-038619.md) | [1.2](/filings/0001628280-25-050422.md) | [0.8 d](/filings/0001628280-26-013569.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(25948.3%)](/filings/0001628280-25-050422.md) | [(2025.7%) d](/filings/0001628280-26-013569.md) | [(3603.3%)](/filings/0001628280-26-031726.md) | [(4787.2%)](/filings/0001628280-26-053883.md) | [(4406.0%)](/filings/0001628280-25-050422.md) | [(5800.5%) d](/filings/0001628280-26-013569.md) | not reported | not reported |
| Net margin | % | [(25128.2%)](/filings/0001628280-25-050422.md) | [(1936.6%) d](/filings/0001628280-26-013569.md) | [(3568.8%)](/filings/0001628280-26-053883.md) | [(4716.7%)](/filings/0001628280-26-053883.md) | [(4129.1%)](/filings/0001628280-25-050422.md) | [(5498.7%) d](/filings/0001628280-26-013569.md) | not reported | not reported |
| Diluted EPS | $ per share | [(0.44)](/filings/0001628280-25-050422.md) | not reported | [(0.40)](/filings/0001628280-26-031726.md) | [(0.41)](/filings/0001628280-26-053883.md) | [(0.32)](/filings/0001628280-25-050422.md) | not reported | [(0.28)](/filings/0001628280-26-031726.md) | [(0.24)](/filings/0001628280-26-053883.md) |
| Free cash flow | $m | [(27.2) d](/filings/0001628280-25-050422.md) | [14.5 d](/filings/0001628280-26-013569.md) | [(51.3)](/filings/0001628280-26-031726.md) | [(43.0) d](/filings/0001628280-26-053883.md) | [(35.3) d](/filings/0001628280-25-050422.md) | [(37.5) d](/filings/0001628280-26-013569.md) | [(42.9)](/filings/0001628280-26-031726.md) | [(41.1) d](/filings/0001628280-26-053883.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001628280-23-007266.md) | [0.0](/filings/0001628280-23-007266.md) | [0.0](/filings/0001628280-25-008884.md) | [3.0](/filings/0001628280-26-013569.md) | [4.6](/filings/0001628280-26-013569.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | [(6787.4%)](/filings/0001628280-26-013569.md) | [(4498.1%)](/filings/0001628280-26-013569.md) |
| Net margin | % | not reported | not reported | not reported | [(6566.6%)](/filings/0001628280-26-013569.md) | [(4342.4%)](/filings/0001628280-26-013569.md) |
| Diluted EPS | $ per share | [(14.19)](/filings/0001628280-23-007266.md) | [(4.19)](/filings/0001628280-24-008116.md) | [(2.18)](/filings/0001628280-25-008884.md) | [(1.65)](/filings/0001628280-26-013569.md) | [(1.35)](/filings/0001628280-26-013569.md) |
| Free cash flow | $m | [(38.2)](/filings/0001628280-23-007266.md) | [(148)](/filings/0001628280-24-008116.md) | [(174)](/filings/0001628280-25-008884.md) | [(130)](/filings/0001628280-26-013569.md) | [(167)](/filings/0001628280-26-013569.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/prme/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2025-08-01 | [GV 2021 GP, L.L.C.](/insiders/1861206.md) | 10% owner | Purchase (P) | 1,500,000 | $3.30 | $5.0m | [Form 4](/filings/0001415889-25-021025.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Alphabet Inc.](/funds/1652044.md) | 2026-06-30 | $61.1m | 16,562,498 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $35.4m | 9,602,041 |  | Added +1,100,333 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $30.8m | 8,348,746 |  | Added +2,101,919 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $28.0m | 7,576,460 |  | Added +1,231,335 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $16.7m | 4,522,640 |  | Added +48,478 |
| [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $14.6m | 3,969,082 |  | Reduced −154,283 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $12.7m | 3,430,518 |  | Added +2,460,093 |
| [Casdin Capital, LLC](/funds/1534261.md) | 2026-06-30 | $11.7m | 3,167,175 |  | Unchanged |
| [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $11.1m | 3,003,904 |  | Added +591 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $10.3m | 2,794,689 |  | Reduced −93,729 |

## Recent filings

[All 297 filings](/companies/prme/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 08:03 ET | [10-Q](/filings/0001628280-26-053883.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053883 |
| 2026-08-06 | 08:02 ET | [8-K](/filings/0001628280-26-053878.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053878 |
| 2026-07-08 | 08:02 ET | [8-K](/filings/0001628280-26-047590.md) | 8.01 Other events | 0001628280-26-047590 |
| 2026-06-08 | 16:10 ET | [8-K](/filings/0001628280-26-041543.md) | 5.07 Shareholder vote results | 0001628280-26-041543 |
| 2026-05-07 | 08:15 ET | [10-Q](/filings/0001628280-26-031726.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031726 |
| 2026-05-07 | 08:10 ET | [8-K](/filings/0001628280-26-031719.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-031719 |
| 2026-04-23 | 08:35 ET | [DEF 14A](/filings/0001628280-26-026697.md) | Proxy statement, period 2025-12-31 | 0001628280-26-026697 |
| 2026-04-16 | 08:15 ET | [8-K](/filings/0001628280-26-025372.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-025372 |
| 2026-03-03 | 08:19 ET | [10-K](/filings/0001628280-26-013569.md) | Annual report, period 2025-12-31 | 0001628280-26-013569 |
| 2026-03-03 | 08:02 ET | [8-K](/filings/0001628280-26-013565.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-013565 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-013569.md), filed Mar 3, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1894562
- Tickers: PRME
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.